You are here: Home / News & Events / News

News

NORD/DIA US Conference on Rare Diseases & Orphan Products: Shaping the Future Now
The 2nd Annual DIA-NORD U.S. Conference on Rare Diseases & Orphan Products: “Shaping the Future Now” took place on October 22-24 in Washington, D.C.
NORD and Advocacy Partners Submit Amicus Brief
NORD and advocacy partners submit amicus brief on Affordable Care Act's minimum coverage provision.
NORD Helps Fund Groundbreaking Study
A groundbreaking study in the journal Nature Medicine suggests what could become the first effective treatment for the debilitating central nervous system disease known as SCA1.
LANDMARK NORD STUDY CONCLUDES FDA IS FLEXIBLE IN REVIEWING THERAPIES FOR RARE DISEASES
NORD today released a landmark report documenting flexibility in the Food and Drug Administration (FDA) review of potential treatments for patients with rare diseases.
NORD And Advocacy Partners Ask FDA To Let Them Help Define Risk
NORD and about 30 of its advocacy partners have sent letters to key officials at the FDA.
NORD and Its Members Submit Risk Letters to FDA Officials
NORD and approximately 30 other patient advocacy organizations have sent letters to key FDA officials regarding the risk tolerance of patients with rare diseases.
NIH Launches Program to Help Start-Up Companies License Medical Technologies
Pres. Obama has announced the launch of a new NIH initiative to help start-up companies license medical technologies for drugs, vaccines, and devices developed by NIH scientists.
Saluting Rare Disease Innovators: NORD 2011 Celebration
On May 17, NORD hosted its 2011 Partners in Progress Celebration at the Andrew W. Mellon Auditorium in Washington DC.
A Day of Dialogue on Rare Diseases and Orphan Products
The NORD Corporate Council met on May 17 in Washington DC for "A Day of Dialogue" with FDA senior staff and other key opinion leaders.
NORD Honors Rare Disease Innovators
Event to Highlight Progress in Research, Advocacy and New Treatments

 
Copyright ©2014 NORD - National Organization for Rare Disorders, Inc. All rights reserved.